Enliven Therapeutics | 144:擬議出售證券
Enliven Therapeutics | 4:持股變動聲明-高管 Hohl Benjamin
Enliven Therapeutics | 144:擬議出售證券
Enliven Therapeutics | 144:擬議出售證券
Enliven Therapeutics | 144:擬議出售證券
Enliven Therapeutics | 4:持股變動聲明-高管 Hohl Benjamin
Enliven Therapeutics | 144:擬議出售證券
Enliven Therapeutics | 144:擬議出售證券
Enliven Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-RA Capital Management, L.P.(2.2%),Peter Kolchinsky(2.2%)等
Enliven Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Venrock Healthcare Capital Partners III, L.P.(8.5%),VHCP Co-Investment Holdings III, LLC(8.5%)等
Enliven Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Citadel Advisors LLC(3.7%),Citadel Advisors Holdings LP(3.7%)等
Enliven Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Fairmount Funds Management LLC(6.8%),Peter Harwin(6.8%)等
Enliven Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Commodore Capital LP(8.7%),Commodore Capital Master LP(8.7%)
Enliven Therapeutics | SC 13G:超過5%持股股東披露文件-Polar Capital Holdings Plc(5.69%),Polar Capital LLP(5.69%)
Enliven Therapeutics | 10-Q:2024財年三季報
Enliven Therapeutics | 8-K:Enliven Therapeutics公佈第三季度財務業績並提供業務最新情況
Enliven Therapeutics | SC 13G:超過5%持股股東披露文件-BlackRock, Inc.(6.2%)
Enliven Therapeutics | 4:持股變動聲明-高管 Hohl Benjamin
Enliven Therapeutics | SC 13G:超過5%持股股東披露文件-BlackRock, Inc.(6.2%)
Enliven Therapeutics | 4:持股變動聲明-高管 Patel Anish